ICER widening assessment of 'unsupported price increases'

Further adding to the semblance that it is now an important voice on US drug prices, the Institute for Clinical and Economic Review (ICER) has published a revised protocol for assessing unsupported price increases.

Through April 19, the ICER is accepting public input on which additional price increases should be included in the 2019 assessment.

This report is to be an annual analysis to determine whether or not significant prescription drug price rises have been accompanied by new clinical evidence that could potentially support those increases.